Kathryn Gold

Title(s)Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Univ of Texas MD Anderson Cancer Center, Houston, TX06/2011Medical Oncology Fellowship
    Hospital of the University of Pennsylvania, Philadelphia, PA06/2008Internal Medicine Residency
    Washington University of St Louis, St Louis, MOMD05/2005Medicine
    Duke University, Durham, NCBS05/2001Chemistry

    Collapse Overview 
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing
    NIH R01CA190628Aug 1, 2015 - Jul 31, 2021
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. Ann Oncol. 2024 May; 35(5):437-447. Yu HA, Baik C, Kim DW, Johnson ML, Hayashi H, Nishio M, Yang JC, Su WC, Gold KA, Koczywas M, Smit EF, Steuer CE, Felip E, Murakami H, Kim SW, Su X, Sato S, Fan PD, Fujimura M, Tanaka Y, Patel P, Sternberg DW, Sellami D, Jänne PA. PMID: 38369013.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    2. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer. 2023 03 01; 129(5):714-727. William WN, Zhang J, Zhao X, Parra ER, Uraoka N, Lin HY, Peng SA, El-Naggar AK, Rodriguez-Canales J, Song J, Gillenwater AM, Wistuba II, Myers JN, Gold KA, Ferrarotto R, Hwu P, Davoli T, Lee JJ, Heymach JV, Papadimitrakopoulou VA, Lippman SM. PMID: 36597662; PMCID: PMC10508302.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    3. A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2022 12; 135:106219. Dennis MJ, Sacco AG, Qi Y, Bykowski J, Pittman E, Chen R, Messer K, Cohen EEW, Gold KA. PMID: 36279618.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    4. Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy. Transl Lung Cancer Res. 2022 Mar; 11(3):452-461. Yu L, Bazhenova L, Gold K, Tran L, Hilburn V, Vu P, Patel SP. PMID: 35399568; PMCID: PMC8988081.
      View in: PubMed   Mentions: 7  
    5. Comparison of Early- and Late-Stage Breast and Colorectal Cancer Diagnoses During vs Before the COVID-19 Pandemic. JAMA Netw Open. 2022 02 01; 5(2):e2148581. Zhou JZ, Kane S, Ramsey C, Akhondzadeh M, Banerjee A, Shatsky R, Gold KA. PMID: 35166787; PMCID: PMC8848202.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsPHPublic Health
    6. A framework and road map for rapid start-up and completion of a COVID-19 vaccine trial: A single clinical trial site experience. J Clin Transl Sci. 2022; 6(1):e21. Rojas C, Spector SA, Cale B, Loughran M, Lazaro L, Mah E, Firestein GS, Gold KA, Wallace M. PMID: 35291217; PMCID: PMC8889226.
      View in: PubMed   Mentions:
    7. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 12; 19(12):1441-1464. Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. PMID: 34902832; PMCID: PMC10203822.
      View in: PubMed   Mentions: 166     Fields:    Translation:Humans
    8. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2022 01; 12(1):74-89. Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, Kim DW, Koczywas M, Gold KA, Steuer CE, Murakami H, Yang JC, Kim SW, Vigliotti M, Shi R, Qi Z, Qiu Y, Zhao L, Sternberg D, Yu C, Yu HA. PMID: 34548309; PMCID: PMC9401524.
      View in: PubMed   Mentions: 101     Fields:    Translation:HumansCTClinical Trials
    9. A Hospital-Wide Intervention to Improve Compliance With TNM Cancer Staging Documentation. J Natl Compr Canc Netw. 2021 08 27; 20(4):351-360.e1. Lee JH, Mohamed T, Ramsey C, Kim J, Kane S, Gold KA, Faraji F, Califano JA. PMID: 34450596.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021 06; 22(6):883-892. Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, Chai-Ho W, Oppelt P, Ghosh D, Bykowski J, Molinolo A, Pittman E, Estrada MV, Gold K, Daniels G, Lippman SM, Natsuhara A, Messer K, Cohen EEW. PMID: 33989559.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    11. Scirrhous carcinoma: A previously undescribed tumor of the oral cavity. Clin Case Rep. 2021 May; 9(5):e03864. DeVries J, Finegersh A, Gold KA, Sharabi AB, Hu J, Orosco RK. PMID: 34084475; PMCID: PMC8142303.
      View in: PubMed   Mentions: 1  
    12. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. Cancer Treat Rev. 2021 Jun; 97:102172. Bourhis J, Stein A, Paul de Boer J, Van Den Eynde M, Gold KA, Stintzing S, Becker JC, Moran M, Schroeder A, Pennock G, Salmio S, Esser R, Ciardiello F. PMID: 33989949.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    13. Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign? CA Cancer J Clin. 2021 01; 71(1):34-46. Cinar P, Bold R, Bosslet BA, Bota DA, Burgess D, Chew HK, Cohen JG, Elquza E, Gold KA, Kamiya E, Karlan BY, McKay RR, Patel SP, Ternavan K, Welborn J, Yamamoto M, Rugo HS. PMID: 32997807; PMCID: PMC7537198.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    14. Rapid onset type 1 diabetes with anti-PD-1 directed therapy. Oncotarget. 2020 Jul 14; 11(28):2740-2746. Yun K, Daniels G, Gold K, Mccowen K, Patel SP. PMID: 32733645; PMCID: PMC7367652.
      View in: PubMed   Mentions: 9     Fields:    
    15. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. J Clin Oncol. 2020 07 20; 38(21):2427-2437. Powell SF, Gold KA, Gitau MM, Sumey CJ, Lohr MM, McGraw SC, Nowak RK, Jensen AW, Blanchard MJ, Fischer CD, Bykowski J, Ellison CA, Black LJ, Thompson PA, Callejas-Valera JL, Lee JH, Cohen EEW, Spanos WC. PMID: 32479189; PMCID: PMC7365766.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    16. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. Clin Cancer Res. 2019 10 15; 25(20):6119-6126. Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D. PMID: 31300452; PMCID: PMC7373320.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    17. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477. Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. PMID: 30596812; PMCID: PMC7360148.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    18. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res. 2019 07 15; 25(14):4211-4223. Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB. PMID: 30814108; PMCID: PMC6635035.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimals
    19. Immunotherapeutic Approaches to the Management of Head and Neck Cancer. Oncology (Williston Park). 2018 12 17; 32(12):617-9, 625-6. Nan X, Gold KA, Cohen E. PMID: 30632130.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. 2018 09 10; 36(26):2693-2701. Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. PMID: 29768119.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    21. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer. 2018 05 15; 124(10):2169-2173. Gold KA, Kies MS, William WN, Johnson FM, Lee JJ, Glisson BS. PMID: 29579331; PMCID: PMC5935588.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    22. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Feb; 105(2):418-424. Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN. PMID: 29217088; PMCID: PMC5783769.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    23. Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. J Thorac Oncol. 2017 10; 12(10):1588-1594. Thress KS, Jacobs V, Angell HK, Yang JC, Sequist LV, Blackhall F, Su WC, Schuler M, Wolf J, Gold KA, Cantarini M, Barrett JC, Jänne PA. PMID: 28751247.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    24. The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 08; 12(8):1280-1287. Sepesi B, Gold KA, Correa AM, Heymach JV, Vaporciyan AA, Roszik J, Dmitrovsky E, Liu X. PMID: 28552766; PMCID: PMC5532070.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    25. Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. Radiology. 2017 05; 283(2):314-340. Cox VL, Bhosale P, Varadhachary GR, Wagner-Bartak N, Glitza IC, Gold KA, Atkins JT, Soliman PT, Hong DS, Qayyum A. PMID: 28418819.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    26. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Apr 20; 35(12):1288-1296. Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. PMID: 28221867.
      View in: PubMed   Mentions: 256     Fields:    Translation:HumansCTClinical Trials
    27. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. PMID: 27836716.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansCTClinical Trials
    28. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016 11 01; 34(31):3740-3748. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D. PMID: 27458307.
      View in: PubMed   Mentions: 252     Fields:    Translation:HumansCTClinical Trials
    29. Sleep and Breathing … and Cancer? Cancer Prev Res (Phila). 2016 11; 9(11):821-827. Owens RL, Gold KA, Gozal D, Peppard PE, Jun JC, Dannenberg AJ, Lippman SM, Malhotra A, UCSD Sleep and Cancer Symposium Group. PMID: 27604751; PMCID: PMC5353979.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    30. The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci Rep. 2016 Jan 05; 6:18652. Ungewiss C, Rizvi ZH, Roybal JD, Peng DH, Gold KA, Shin DH, Creighton CJ, Gibbons DL. PMID: 26728244; PMCID: PMC4700473.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimalsCells
    31. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016 Feb; 17(2):234-242. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI, study investigators. PMID: 26708155; PMCID: PMC4752892.
      View in: PubMed   Mentions: 289     Fields:    Translation:HumansCTClinical Trials
    32. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head Neck. 2016 04; 38 Suppl 1:E1554-61. Nien HH, Sturgis EM, Kies MS, El-Naggar AK, Morrison WH, Beadle BM, Johnson FM, Gunn GB, Fuller CD, Phan J, Gold KA, Frank SJ, Skinner H, Rosenthal DI, Garden AS. PMID: 26595157.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    33. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer. 2016 Feb 15; 122(4):534-45. Xing Y, Zhang J, Lin H, Gold KA, Sturgis EM, Garden AS, Lee JJ, William WN. PMID: 26554754; PMCID: PMC4742373.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    34. Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. Int J Cancer. 2016 Mar 01; 138(5):1290-7. Shoultz-Henley S, Garden AS, Mohamed AS, Sheu T, Kroll MH, Rosenthal DI, Gunn GB, Hayes AJ, French C, Eichelberger H, Kalpathy-Cramer J, Smith BD, Phan J, Ayoub Z, Lai SY, Pham B, Kies M, Gold KA, Sturgis E, Fuller CD. PMID: 26414107; PMCID: PMC4779600.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    35. New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2015 Oct; 4(5):553-9. Carrizosa DR, Gold KA. PMID: 26629424; PMCID: PMC4630527.
      View in: PubMed   Mentions: 23  
    36. FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Aug; 10(8):1131-2. Gold KA, Erasmus JJ. PMID: 26200266.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    37. Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. Head Neck. 2016 04; 38 Suppl 1:E925-33. Takiar V, Ma D, Garden AS, Li J, Rosenthal DI, Beadle BM, Frank SJ, Fuller CD, Gunn GB, Morrison WH, Hutcheson K, El-Naggar AK, Gold KA, Kupferman ME, Phan J. PMID: 25994561.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    38. The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target. Mol Cancer Ther. 2015 Jun; 14(6):1273-5. Liu X, Gold KA, Dmitrovsky E. PMID: 25995438; PMCID: PMC4599702.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015 Apr; 10(4):682-90. Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William WN. PMID: 25590605; PMCID: PMC4368494.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    40. ROS1--targeting the one percent in lung cancer. N Engl J Med. 2014 Nov 20; 371(21):2030-1. Gold KA. PMID: 25409376.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    41. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. PMID: 25301631; PMCID: PMC4354858.
      View in: PubMed   Mentions: 508     Fields:    Translation:Humans
    42. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9). Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. PMID: 25214559; PMCID: PMC4200057.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    43. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 2014 Oct; 19(10):1040-1. Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. PMID: 25170013; PMCID: PMC4201000.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    44. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014 Apr 01; 20(7):1946-54. Gold KA, Kim ES, Liu DD, Yuan P, Behrens C, Solis LM, Kadara H, Rice DC, Wistuba II, Swisher SG, Hofstetter WL, Lee JJ, Hong WK. PMID: 24366692; PMCID: PMC4018222.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    45. Afatinib in the treatment of head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2014 Jan; 23(1):135-43. Ferrarotto R, Gold KA. PMID: 24266694.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    46. Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it. JAMA Otolaryngol Head Neck Surg. 2013 Nov; 139(11):1127-34. Hutcheson KA, Bhayani MK, Beadle BM, Gold KA, Shinn EH, Lai SY, Lewin J. PMID: 24051544; PMCID: PMC3969836.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    47. Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):1071-7. Wang H, Liao Z, Zhuang Y, Xu T, Nguyen QN, Levy LB, O'Reilly M, Gold KA, Gomez DR. PMID: 24161424; PMCID: PMC4162095.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    48. The role of systemic treatment before, during, and after definitive treatment. Otolaryngol Clin North Am. 2013 Aug; 46(4):645-56. Gold KA, Neskey M, William WN. PMID: 23910475; PMCID: PMC3734377.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8. William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. PMID: 23287849; PMCID: PMC3549050.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    50. Natural-agent mechanisms and early-phase clinical development. Top Curr Chem. 2013; 329:241-52. Wang JL, Gold KA, Lippman SM. PMID: 22851156.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    51. Personalizing lung cancer prevention through a reverse migration strategy. Top Curr Chem. 2013; 329:221-40. Gold KA, Kim ES, Wistuba II, Hong WK. PMID: 22752582; PMCID: PMC3737590.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    52. Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila). 2013 Jan; 6(1):8-17. Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II. PMID: 23087048; PMCID: PMC3774536.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCellsCTClinical Trials
    53. Sorafenib in non-small cell lung cancer. Expert Opin Investig Drugs. 2012 Sep; 21(9):1417-26. Zhang J, Gold KA, Kim E. PMID: 22725255.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    54. New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res. 2012 Jun 01; 18(11):3002-7. Gold KA, Wistuba II, Kim ES. PMID: 22461458; PMCID: PMC3737591.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    55. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila). 2011 Jul; 4(7):962-72. Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. PMID: 21733820; PMCID: PMC3171137.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    56. Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model. Cancer Prev Res (Phila). 2011 Aug; 4(8):1306-15. Lee J, Ryu SH, Kang SM, Chung WC, Gold KA, Kim ES, Hittelman WN, Ki Hong W, Koo JS. PMID: 21505178; PMCID: PMC3151315.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    57. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann Oncol. 2009 Sep; 20(9):1455-1457. William WN, Gold KA, Kim ES. PMID: 19704160.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. Role of molecular markers and gene profiling in head and neck cancers. Curr Opin Oncol. 2009 May; 21(3):206-11. Gold KA, Kim ES. PMID: 19346943.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    59. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer. 2009 Mar 01; 115(5):922-35. Gold KA, Lee HY, Kim ES. PMID: 19156911.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    60. Breast and cervix cancer screening among multiethnic women: role of age, health, and source of care. Prev Med. 1999 Apr; 28(4):418-25. Mandelblatt JS, Gold K, O'Malley AS, Taylor K, Cagney K, Hopkins JS, Kerner J. PMID: 10090871.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansPHPublic Health
    61. Is HIV infection a cofactor for cervical squamous cell neoplasia? Cancer Epidemiol Biomarkers Prev. 1999 Jan; 8(1):97-106. Mandelblatt JS, Kanetsky P, Eggert L, Gold K. PMID: 9950246.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    62. Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. J Allergy Clin Immunol. 1997 Jul; 100(1):16-22. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. PMID: 9257782.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    Kathryn's Networks
    Concepts (275)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (44)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (59)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California